Skip to main content
News & Events

Biome Diagnostics mentioned in Financial Times

By January 26, 2022No Comments

VIENNA, December 2021: For the first time in the history of the company, Biome Diagnostics has been mentioned in the FInancial Times. (

Generally, Austria is growing as a very attractive city for entrepreneurs, and has already set itself on the map as an innovation hub for many start-ups.

Kit Gillet has shared his thoughts in an article in Financial Times highlighting what Austria has to offer for start-ups. He also focuses on the community of entrepreneurial women that supports and empowers females. Of course, he has taken the testimony of our co-founder Barbara Sladek!

We are also part of the increasingly long list of young companies that decided to start their activity in Austria, now a recognised meeting point for innovators and entrepreneurs!

About BiomeOne®

BiomeOne describes the current efforts of BiomeDx towards the world’s first stool-based response prediction test for immunotherapy (ICI). Currently, the biomarker is tested in three tumor types: non-small-cell lung cancer, renal cell carcinoma and malignant melanoma. Early research efforts support the idea of a tumor agnostic biomarker that can be used for any tumor type. Read more on BiomeOne.

About BiomeDx®

Biome Diagnostics GmbH (BiomeDx) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.